Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CI 1040

Known as: CI-1040, CI1040 
 
National Institutes of Health

Related topics

Related topics

1 relation
PD 184352

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase… Expand
Highly Cited
2009
Highly Cited
2009
Simvastatin Inhibits Angiotensin II–Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E–Knockout Mice: Possible Role of ERK
Objective—Abdominal aortic aneurysm (AAA) is a life-threatening disease affecting almost 10% of the population over age 65… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Highly Cited
2008
Highly Cited
2008
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2007
Highly Cited
2007
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
CONTEXT Targeting MAPK kinase (MEK) in the MAPK pathway is a potentially effective therapeutic strategy for thyroid cancer… Expand
Highly Cited
2005
Highly Cited
2005
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
PURPOSE This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD… Expand
Highly Cited
2005
Highly Cited
2005
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.
PD184352/CI-1040 is a potent and selective MEK1/2 inhibitor that represents the first MEK-targeted agent to enter clinical trials… Expand
Highly Cited
2005
Highly Cited
2005
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2004
Highly Cited
2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
PURPOSE This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral… Expand
Review
2003
Review
2003
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
Several key growth factors, cytokines, and proto-oncogenes transduce their growth- and differentiation-promoting signals through… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE